Pharmacological advances in mitochondrial therapy

EBioMedicine. 2021 Mar:65:103244. doi: 10.1016/j.ebiom.2021.103244. Epub 2021 Feb 26.

Abstract

Mitochondria play a vital role in cellular metabolism and are central mediator of intracellular signalling, cell differentiation, morphogenesis and demise. An increasingly higher number of pathologies is linked with mitochondrial dysfunction, which can arise from either genetic defects affecting core mitochondrial components or malfunctioning pathways impairing mitochondrial homeostasis. As such, mitochondria are considered an important target in several pathologies spanning from neoplastic to neurodegenerative diseases as well as metabolic syndromes. In this review we provide an overview of the state-of-the-art in mitochondrial pharmacology, focusing on the novel compounds that have been generated in the bid to correct mitochondrial aberrations. Our work aims to serve the scientific community working on translational medical science by highlighting the most promising pharmacological approaches to target mitochondrial dysfunction in disease.

Keywords: Mitochondria-targeted and untargeted agents; Mitochondrial diseases; Mitochondrial dysfunction in pathology.

Publication types

  • Review

MeSH terms

  • Antioxidants / pharmacology
  • Antioxidants / therapeutic use*
  • Humans
  • Mitochondria / drug effects
  • Mitochondria / metabolism*
  • Mitochondrial Diseases / drug therapy*
  • Mitochondrial Diseases / pathology
  • Mitochondrial Dynamics / drug effects
  • Neurodegenerative Diseases / drug therapy
  • Neurodegenerative Diseases / pathology
  • Oxidative Phosphorylation / drug effects
  • Pyrazines / pharmacology
  • Pyrazines / therapeutic use
  • Ubiquinone / analogs & derivatives
  • Ubiquinone / pharmacology
  • Ubiquinone / therapeutic use

Substances

  • Antioxidants
  • Pyrazines
  • Ubiquinone
  • idebenone
  • acipimox